Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down). Cardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients. Traditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA. This is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.
Background and Rationale Cardioneuroablation is an emerging treatment for vagally-mediated bradyarrhythmias, including symptomatic sinus bradycardia, atrioventricular blocks, and vasovagal syncope with a cardioinhibitory component . The procedure targets ganglionated plexi located in the epicardial fat and myocardium, which contain parasympathetic nerve endings. While radiofrequency (RF) energy is the standard modality for CNA, epicardial fat may limit RF lesion formation when fat thickness exceeds 3 mm. Cryoablation, by contrast, uniformly cools tissue without energy dissipation in fat, potentially offering more consistent ganglion ablation. To date, no clinical study has compared focal cryoablation versus RF ablation specifically for cardioneuroablation. Objectives Primary: To compare the efficacy of focal cryoablation versus RF ablation for cardioneuroablation in preventing bradyarrhythmia recurrence. Secondary: To compare the safety profile of both techniques, including periprocedural complications and inappropriate sinus tachycardia. Study Design This is a prospective, non-randomized, parallel-group study conducted at a single center (Cardiology Research Institute, Tomsk NRMC). Eligible patients aged 18-60 years with symptomatic vagally-mediated bradyarrhythmias (confirmed by positive atropine test and/or EP study) are assigned non-randomly to either: Group 1 (RF-CNA, N=30): Radiofrequency ablation using TactiFlex™ SE catheter (Abbott), power 45W, target AI 45, with irrigation Group 2 (Cryo-CNA, N=30): Focal cryoablation using Freezor™ Xtra 6mm catheter (Medtronic), target temperature -75°C, 240 seconds per application Procedures All procedures are performed under intravenous sedation. After establishing venous access, a 3D electroanatomical map of the right atrium is created using the EnSite™ X system with HD Grid mapping catheter. Ganglionated plexi are identified using spectral analysis (OTNF algorithm) and anatomical landmarks (RAGP and IRGP). Ablation is applied at identified sites. Intraprocedural endpoints include: Reduction of SNRT \<1500 ms and cSNRT \<525 ms Wenckebach point ≥140 bpm AV node ERP \>300 ms Absence of bradycardic response to phenylephrine (\<10% heart rate reduction) Follow-up Patients are followed at 6 and 12 months post-procedure with clinical assessment, 12-lead ECG, and 24-hour Holter monitoring. Statistical Considerations The planned sample size is 60 patients (30 per group). Quantitative variables will be presented as mean±SD or median \[Q1;Q3\]. Paired t-test or Wilcoxon test will be used for pre-post comparisons. Between-group comparisons will use Mann-Whitney U test. Statistical significance set at p\<0.05.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Focal cryoablation of right atrial ganglionated plexi using Freezor™ Xtra 6mm catheter (Medtronic) at -75°C for 240 seconds per application. 3-5 applications per GP zone. Positioned by fluoroscopy and impedance-based tracking in EnSite™ X system.
Radiofrequency ablation of right atrial ganglionated plexi using TactiFlex™ SE catheter (Abbott) with power up to 45W, temperature 50°C, target AI 45, with irrigation. 3-5 applications per GP zone. Guided by EnSite™ X mapping system and spectral analysis (OTNF).
Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Tomsk, Tomsk Oblast, Russia
RECRUITINGRecurrence of Bradyarrhythmia or Syncope
Documented recurrence of symptomatic bradyarrhythmia (sinus bradycardia \<40 bpm, pause \>3 sec, AV block) or syncope confirmed by ECG or Holter
Time frame: 12 months
Pericardial Effusion or Hemopericardium
Pericardial effusion or hemopericardium requiring intervention, confirmed by echocardiography
Time frame: Periprocedural (7 days)
Inappropriate Sinus Tachycardia
Sustained sinus tachycardia \>100 bpm without cause, requiring beta-blocker therapy
Time frame: 12 months
Vascular Access Complications
Hematoma, pseudoaneurysm, or AV fistula requiring treatment, confirmed by ultrasound
Time frame: Periprocedural (7 days)
Change in Minimum Heart Rate
Absolute change in minimum heart rate (bpm) on 24-hour Holter from baseline to 6 months
Time frame: Baseline to 6 months
Change in Maximum Heart Rate
Absolute change in maximum heart rate (bpm) on 24-hour Holter from baseline to 6 months
Time frame: Baseline to 6 months
Change in Electrophysiological Parameters
Normalization of cSNRT \<525 ms, Wenckebach point ≥140 bpm, AV-ERP \>300 ms
Time frame: Intraprocedural
Change in Mean Heart Rate
Absolute change in minimum heart rate (bpm) on 24-hour Holter from baseline to 6 months
Time frame: Baseline to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.